Robert A Harrington
Department of Medicine
Dr. Robert A. Harrington is an interventional cardiologist and the Arthur L. Bloomfield Professor of Medicine and Chairman of the Department of Medicine at Stanford University. Dr. Harrington was previously the Richard Sean Stack, MD Distinguished Professor and the Director of the Duke Clinical Research Institute (DCRI) at Duke University. His research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issue of risk stratification in the care of patients with acute ischemic coronary syndromes, building local, national and international collaborations for the efficient conduct of innovative clinical research and trying to better understand and improve upon the methodology of clinical research. His research has been extensively funded through NIH, NIA, other peer reviewed agencies and private industry. Committed to training and mentorship, Harrington has served as the principal mentor for more than 20 post-doctoral clinical research fellows focused on cardiovascular research. He has authored more than 520 peer-reviewed manuscripts, reviews, book chapters, and editorials. Thomson Reuters lists him as one of the most cited investigators in clinical medicine from 2002-2014. He is a deputy editor of JAMA Cardiology and an editorial board member for the Journal of the American College of Cardiology. He has served as editor of five textbooks and is a senior editor of the 13th and 14th editions of Hurst's The Heart, one of the leading textbooks of cardiovascular medicine. He has been a member of the NHLBI's Clinical Trials Study Section and the IOM's Working Group on Data Sharing. He served as a member of the NIH NCATS Advisory Council Working Group on the IOM CTSA Program. He is currently serving a second term as a member and the chair of the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee.